mrna-4157,pembrolizumab
moderna,merck
['merck', 'moderna']
 neoantigen vaccine with pd1 with improved rfs bs pd1 alone hr 0.56. 44% benefit in pfs. #aacr23 
Chief of Research and Immunotherapy  •  ImmunoOncology  •  Phase I  Clinical Trials  •  Melanoma  •  Cutaneous Oncology